AUTHOR=Zheng Jianfeng , Chen Wenjuan , Yi Xuemei , Yu Ning , Ding Yangfeng , Gao Yunlu 

TITLE=Long-term efficacy and safety of guselkumab in Chinese patients with moderate-to-severe plaque psoriasis

JOURNAL=Frontiers in Medicine

VOLUME=Volume 10 - 2023

YEAR=2023

URL=https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2023.1285972

DOI=10.3389/fmed.2023.1285972

ISSN=2296-858X

ABSTRACT=Background: randomized controlled trials indicated guselkumab, the first anti-interleukin-23 monoclonal antibody, is efficacious in plaque psoriasis. However, guselkumab's performance in real life is scarcely examined, especially in China.Objectives: this work aimed to assess the long-term effectiveness of guselkumab in actual clinical practice in China.Methods: a retrospective study was performed for plaque psoriasis cases administered guselkumab in Shanghai Skin Disease Hospital between January 2020 and September 2022.Results: totally 37 patients were included (29 males, 78.4%), with a mean follow-up period of 72.3 ± 26.7 weeks (range of 12-108 weeks). At baseline, clinical examination revealed a mean PASI of 12.3 ± 7.1, a mean BSA of 17.1 ± 18.1 and a mean DLQI of 7.7 ± 4.3. 22 (62.9%) and 17 (48.6%) cases achieved PASI90 and PASI100 responses at week 28. From week 60 to week 92, > 80% of cases achieved PASI90 and PASI100 responses. Regarding safety, no cases of serious AEs were recorded. A total of 9 cases (24.3%) had different abnormal results in HBV markers and 2 were T-SPOT positive. There was no hepatitis B virus or tuberculosis outbreak in these patients.this real-life study confirmed the long-term efficacy and safety of guselkumab in daily clinical practice.